![Neon sign that says pharmacy.](/sites/default/files/styles/16x9_one_third_default_1x/public/2023-05/rt_promotional_images_2_1.png?h=317ad4a3&itok=CR8YYdBr)
The U.S. Food and Drug Administration has approved naloxone nasal spray (Narcan)—a medicine that rapidly reverses an opioid overdose—for over-the-counter use.
The increased availability of naloxone will help underserved communities, but the price of Narcan could increase and stigma for people who use opioids may remain, according to a new editorial by Rafael E. Pérez-Figueroa, associate dean for community engagement and public health practice and an associate professor in the Department of Urban-Global Public Health at the Rutgers School of Public Health. The editorial was published in the The BMJ.